Tongyang Life Insurance announced on June 16 that it has launched the “(Non-participating) Comprehensive Cancer Hospital Integrated Treatment Rider,” which aims to ease the financial burden that can arise during cancer treatment and to enhance coverage at each stage of treatment.


Tongyang Life Insurance Launches "(Non-participating) Comprehensive Cancer Hospital Integrated Treatment Rider"... "Enhanced Coverage for Each Stage of Cancer Treatment" View original image

This product provides coverage throughout the entire cancer care journey under a single rider, from cancer screening and major treatments to follow-up care. In particular, the scope of coverage has been expanded from tests such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound examinations, and specific next-generation sequencing (NGS) gene panel tests, to high-cost treatments such as Da Vinci robotic cancer surgery, targeted anti-cancer drug-approved treatments, certain immuno-oncology drug-approved treatments, and proton radiation therapy for cancer. It also includes pain alleviation therapy and rehabilitation therapy, helping to reduce the financial burden that may arise during follow-up treatment.


In addition, even if a policyholder meets the insurance payout requirements and receives a payout in a given year, if a new reason for payout arises the following year, the policy can provide repeated coverage according to the standards set in the terms and conditions. Coverage is provided within the annual policy limit even if multiple items apply.


The “(Non-participating) Comprehensive Cancer Hospital Integrated Treatment Rider” is available through the “(Non-participating) Woori WON Total Protection Insurance” product. Individuals can enroll from age 15 up to age 80. For a 40-year-old male, with a 100 million won coverage amount, standard underwriting, whole life coverage, and a 20-year premium payment period, the monthly premium is in the 50,000 won range.



A Tongyang Life Insurance representative stated, “In the current cancer insurance market, the importance of providing practical coverage for costs that arise during the treatment process, beyond the lump-sum benefit paid upon cancer diagnosis, is growing. This rider is meaningful in that it helps customers reduce their treatment expenses and focus more on their recovery.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing